30-day Readmission And Economic Burden Among Patients With Chronic Diastolic Heart Failure With Coexisting Type 2 Diabetes And Chronic Kidney Disease Iii/iv
Hira Akhlaq,Ndausung Udongwo,Anmol Johal,Anton Mararenko,Viraaj Pannu,Steven Imburgio,Abbas Alshami,Brett Sealove,Jesus Almendral,Joseph Heaton
DOI: https://doi.org/10.1016/j.cardfail.2023.10.390
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Left ventricular diastolic dysfunction resulting in heart failure with preserved ejection fraction (HFpEF) can be further exacerbated by concurrent chronic conditions. In patients with HFpEF, type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD), there is a significant increase in all-cause and cardiovascular mortality. While all three conditions commonly coexist, there is limited data and very few studies investigating readmission, mortality, length of stay, and healthcare utilization when all three diseases are present. We sought to determine the effect of CKDIII/IV on the 30-day readmission rate (30-dr) for HFpEF in individuals with coexisting T2DM and its impact on healthcare utilization and economic burden. We conducted a retrospective study of patients admitted with HFpEF with coexisting T2DM between 2016 and 2020 using the Nationwide Readmissions Database. Variables were identified using their ICD-10 codes. Patients were included if they were at least 18 years of age with T2DM and admitted with a primary diagnosis of HFpEF. They were then stratified by the presence or absence of CKD III/IV during their index admission. The primary outcome was 30-dr, while secondary outcomes were length of stay (LOS), inpatient mortality, and resource utilization defined by hospital charge (HC). Multivariate linear, Cox, and logistic regression analyses were performed. Between 2016 and 2020 164,5569 patients with HFpEF and coexisting T2DM met the inclusion criteria. The mean age was 72.6 ± 11.8 years and 58% (n = 97,076) were females. Of these, 34.6% (n = 56,863) had CKD III/IV. The mean age was 74.5 ± 10.8 years in the CKD III/IV group versus 71.6 ± 12.1 in the non-CKD III/IV group (adjusted Wald test p < 0.001). Multivariate logistic regression models adjusting for other clinical variables showed higher odds for 30-dr (OR 1.07 95% CI 1.02 - 1.12, p < 0.001) in patients with CKD III/IV when compared to the non-CKD III/IV group. The mean LOS on index admission was 5.7 ± 5.1 days (CKD III/IV) versus 5.2 ± 5.1 (non-CKD III/IV). On readmission, LOS was higher in the CKD III/IV group compared to the non-CKD III/IV group (6.6 ± 5.5 days versus 5.9 ± 5.7 (adjusted Wald test, p < 0.001)). HC on index admission had a mean of $11,916.7 versus $11,256.7, compared to $13,984.8 versus $14,032.4 on readmission r in CKD III/IV versus non-CKD III/IV group, respectively (adjusted Wald test, p < 0.001). Cox regression analysis revealed no statistically significant differences in the hazard ratio for inpatient mortality between the two groups (HR 0.89 95% CI 0.78 - 1.01, p = 0.069). Patients with HFpEF and T2DM with concurrent CKD III/IV have an increased risk of readmission within 30 days and have a longer LOS and higher healthcare costs on their index admission as well as during their 30-dr. Preventing readmission in this high-risk population is necessary to promote better outcomes and reduce the economic burden on the healthcare system.
cardiac & cardiovascular systems